286 related articles for article (PubMed ID: 37361998)
1. How does Nogo receptor influence demyelination and remyelination in the context of multiple sclerosis?
Rashidbenam Z; Ozturk E; Pagnin M; Theotokis P; Grigoriadis N; Petratos S
Front Cell Neurosci; 2023; 17():1197492. PubMed ID: 37361998
[TBL] [Abstract][Full Text] [Related]
2. Can We Design a Nogo Receptor-Dependent Cellular Therapy to Target MS?
Kim MJ; Kang JH; Theotokis P; Grigoriadis N; Petratos S
Cells; 2018 Dec; 8(1):. PubMed ID: 30577457
[TBL] [Abstract][Full Text] [Related]
3. How does Nogo-A signalling influence mitochondrial function during multiple sclerosis pathogenesis?
Nheu D; Petratos S
Neurosci Biobehav Rev; 2024 Jun; 163():105767. PubMed ID: 38885889
[TBL] [Abstract][Full Text] [Related]
4. Modulation of the Microglial Nogo-A/NgR Signaling Pathway as a Therapeutic Target for Multiple Sclerosis.
Nheu D; Ellen O; Ye S; Ozturk E; Pagnin M; Kertadjaja S; Theotokis P; Grigoriadis N; McLean C; Petratos S
Cells; 2022 Nov; 11(23):. PubMed ID: 36497029
[TBL] [Abstract][Full Text] [Related]
5. Nogo-A and LINGO-1: Two Important Targets for Remyelination and Regeneration.
Kalafatakis I; Papagianni F; Theodorakis K; Karagogeos D
Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901909
[TBL] [Abstract][Full Text] [Related]
6. Nogo receptor-Fc delivered by haematopoietic cells enhances neurorepair in a multiple sclerosis model.
Ye S; Theotokis P; Lee JY; Kim MJ; Nheu D; Ellen O; Bedford T; Ramanujam P; Wright DK; McDonald SJ; Alrehaili A; Bakhuraysah M; Kang JH; Siatskas C; Tremblay CS; Curtis DJ; Grigoriadis N; Monif M; Strittmatter SM; Petratos S
Brain Commun; 2023; 5(2):fcad108. PubMed ID: 37091588
[TBL] [Abstract][Full Text] [Related]
7. Nogo-A antibodies enhance axonal repair and remyelination in neuro-inflammatory and demyelinating pathology.
Ineichen BV; Kapitza S; Bleul C; Good N; Plattner PS; Seyedsadr MS; Kaiser J; Schneider MP; Zörner B; Martin R; Linnebank M; Schwab ME
Acta Neuropathol; 2017 Sep; 134(3):423-440. PubMed ID: 28646336
[TBL] [Abstract][Full Text] [Related]
8. Nogo receptor expression in microglia/macrophages during experimental autoimmune encephalomyelitis progression.
Alrehaili AA; Lee JY; Bakhuraysah MM; Kim MJ; Aui PM; Magee KA; Petratos S
Neural Regen Res; 2018 May; 13(5):896-907. PubMed ID: 29863021
[TBL] [Abstract][Full Text] [Related]
9. Limiting Neuronal Nogo Receptor 1 Signaling during Experimental Autoimmune Encephalomyelitis Preserves Axonal Transport and Abrogates Inflammatory Demyelination.
Lee JY; Kim MJ; Thomas S; Oorschot V; Ramm G; Aui PM; Sekine Y; Deliyanti D; Wilkinson-Berka J; Niego B; Harvey AR; Theotokis P; McLean C; Strittmatter SM; Petratos S
J Neurosci; 2019 Jul; 39(28):5562-5580. PubMed ID: 31061088
[TBL] [Abstract][Full Text] [Related]
10. Limiting multiple sclerosis related axonopathy by blocking Nogo receptor and CRMP-2 phosphorylation.
Petratos S; Ozturk E; Azari MF; Kenny R; Lee JY; Magee KA; Harvey AR; McDonald C; Taghian K; Moussa L; Mun Aui P; Siatskas C; Litwak S; Fehlings MG; Strittmatter SM; Bernard CC
Brain; 2012 Jun; 135(Pt 6):1794-818. PubMed ID: 22544872
[TBL] [Abstract][Full Text] [Related]
11. Oligodendrocyte progenitor cell recruitment and remyelination in multiple sclerosis: the more, the merrier?
Tepavčević V; Lubetzki C
Brain; 2022 Dec; 145(12):4178-4192. PubMed ID: 36093726
[TBL] [Abstract][Full Text] [Related]
12. Inactivation of sphingosine-1-phosphate receptor 2 (S1PR2) decreases demyelination and enhances remyelination in animal models of multiple sclerosis.
Seyedsadr MS; Weinmann O; Amorim A; Ineichen BV; Egger M; Mirnajafi-Zadeh J; Becher B; Javan M; Schwab ME
Neurobiol Dis; 2019 Apr; 124():189-201. PubMed ID: 30468865
[TBL] [Abstract][Full Text] [Related]
13. That's a Wrap! Molecular Drivers Governing Neuronal Nogo Receptor-Dependent Myelin Plasticity and Integrity.
Petratos S; Theotokis P; Kim MJ; Azari MF; Lee JY
Front Cell Neurosci; 2020; 14():227. PubMed ID: 32848619
[TBL] [Abstract][Full Text] [Related]
14. Recent Advances on Immunosuppressive Drugs and Remyelination Enhancers for the Treatment of Multiple Sclerosis.
Cadenas-Fernández J; Ahumada-Pascual P; Andreu LS; Velasco A
Curr Pharm Des; 2021 Oct; 27(30):3273-3280. PubMed ID: 33504299
[TBL] [Abstract][Full Text] [Related]
15. Remyelination in multiple sclerosis: realizing a long-standing challenge.
Aharoni R
Expert Rev Neurother; 2015; 15(12):1369-72. PubMed ID: 26558886
[TBL] [Abstract][Full Text] [Related]
16. Oligodendroglia in cortical multiple sclerosis lesions decrease with disease progression, but regenerate after repeated experimental demyelination.
Rodriguez EG; Wegner C; Kreutzfeldt M; Neid K; Thal DR; Jürgens T; Brück W; Stadelmann C; Merkler D
Acta Neuropathol; 2014 Aug; 128(2):231-46. PubMed ID: 24563023
[TBL] [Abstract][Full Text] [Related]
17. Distinct patterns of glia repair and remyelination in antibody-mediated demyelination models of multiple sclerosis and neuromyelitis optica.
Liu Y; Given KS; Owens GP; Macklin WB; Bennett JL
Glia; 2018 Dec; 66(12):2575-2588. PubMed ID: 30240044
[TBL] [Abstract][Full Text] [Related]
18. The role of oligodendrocytes and oligodendrocyte progenitors in CNS remyelination.
Keirstead HS; Blakemore WF
Adv Exp Med Biol; 1999; 468():183-97. PubMed ID: 10635029
[TBL] [Abstract][Full Text] [Related]
19. Remyelination in multiple sclerosis from the miRNA perspective.
Maciak K; Dziedzic A; Saluk J
Front Mol Neurosci; 2023; 16():1199313. PubMed ID: 37333618
[TBL] [Abstract][Full Text] [Related]
20. Myelin recovery in multiple sclerosis: the challenge of remyelination.
Podbielska M; Banik NL; Kurowska E; Hogan EL
Brain Sci; 2013 Aug; 3(3):1282-324. PubMed ID: 24961530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
